What Is Petrelintide? Roche and Zealand’s Amylin-Based Approach to Obesity

What is Petrelintide?

Petrelintide is a once-weekly long-acting amylin analog designed to mimic amylin, a hormone involved in satiety signaling and meal regulation. It is being developed by Roche and Zealand Pharma for the treatment of overweight and obesity. For a side-by-side analysis against Novo Nordisk’s amylin combination, see our petrelintide vs CagriSema comparison.

The key distinction: GLP-1 receptor agonists reduce appetite through incretin-mediated pathways. Petrelintide engages a separate amylin-mediated satiety mechanism. That makes petrelintide relevant both as a standalone agent and as a potential combination partner for incretin-based therapies — a modular approach rather than a head-to-head replacement. Our CagriSema amylin and GLP-1 profile explains how other programmes are leveraging the amylin pathway.

Petrelintide should not be described as “another GLP-1 drug.” It is a mechanistically distinct compound.

What Did the ZUPREME-1 Phase 2 Trial Show?

Roche’s March 5, 2026 investor update is the current anchor source for petrelintide efficacy data. The ZUPREME-1 dose-finding trial enrolled 493 adults with obesity or overweight and randomized them across five treatment arms compared in a double-blind, placebo-controlled design. The trial period spanned 42 weeks of treatment following a screening period of 2–4 weeks.

All participants followed a reduced-calorie diet and increased physical activity protocol as background lifestyle intervention. The primary endpoint was percentage change in body weight from baseline to week 42. The topline results showed a clear dose-response relationship, with participants in the highest active dose arm achieving an average weight loss of 10.7% of body weight compared to 1.7% with placebo.

The tolerability data are particularly significant. Gastrointestinal side effects remain a primary concern with the current generation of obesity medicines, and the tolerability profile reported by Roche directly addresses that clinical question. For context on how petrelintide fits into the broader competitive landscape, see our retatrutide vs tirzepatide vs CagriSema comparison.

Why Does Tolerability Matter So Much for Petrelintide?

The petrelintide development thesis extends beyond raw weight-loss numbers. Roche has stated that the tolerability profile supports further development of petrelintide both as a monotherapy and as a combination partner.

This is why the planned petrelintide + CT-388 combination study carries strategic importance. If Roche can pair an amylin-based backbone with an incretin-class compound and maintain a favorable tolerability profile, it could build a differentiated obesity franchise — not a single-product story. For a broader look at the research peptide landscape, see our best research peptides 2026 guide.

How Amylin Works: The Biology Behind Petrelintide

Amylin is a 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells in response to ingested nutrients. When you eat a meal, pancreatic beta cells release both insulin and amylin into the bloodstream. While insulin manages blood glucose uptake, amylin plays a complementary role in satiety signaling, gastric emptying regulation, and post-meal glucagon suppression.

In people with obesity or overweight, the amylin signaling pathway is often impaired. Restoring sensitivity to amylin-mediated signals is the core pharmacological rationale behind petrelintide. By acting as a long-acting amylin analog, once-weekly petrelintide aims to replicate the physiological effects of endogenous amylin — reducing food intake, slowing gastric emptying, and promoting satiety — without requiring multiple daily injections.

This mechanism is fundamentally different from GLP-1 receptor agonists. GLP-1 drugs target incretin receptors to suppress appetite through a separate pathway. The fact that petrelintide and GLP-1 receptor agonists operate through distinct biological systems is why co-administration of both drug classes is being explored in clinical practice and in the obesity treatment pipeline.

Amylin Analog vs Native Amylin

Native human amylin is notoriously unstable — it aggregates and forms amyloid fibrils rapidly in solution. Previous amylin-based therapies like pramlintide (Symlin) required multiple daily injections due to short half-life and chemical instability. Zealand Pharma engineered petrelintide as a long-acting amylin analog with improved chemical and physical stability, enabling once-weekly subcutaneous administration rather than the three-times-daily dosing required by pramlintide.

The chemical and physical stability improvements in petrelintide include modifications that maintain structural integrity at neutral pH and prevent amyloid aggregation. This physical stability profile is a key differentiator that makes once-weekly petrelintide practical for weight management in clinical settings.

Preclinical Evidence: Petrelintide in DIO Rat Models

Before entering human clinical trials, petrelintide demonstrated consistent body weight reduction in diet-induced obesity (DIO) rat models. In these preclinical studies, DIO rats fed a high-fat diet were treated with petrelintide at multiple dose levels. Petrelintide demonstrated significant reductions in body weight compared to vehicle-treated controls, with changes driven primarily by reduced food intake rather than metabolic toxicity.

Critically, DIO rats treated with petrelintide showed preferential loss of fat mass while preserving lean mass — a body composition outcome that has become increasingly important in obesity treatment research. The ratio of fat mass to lean mass shifted favorably, suggesting that petrelintide’s weight reduction effects are not simply due to caloric restriction alone but involve pathway-specific metabolic signaling through the amylin receptor system.

In high-fat diet DIO rat studies, petrelintide also reduced food intake in a dose-dependent manner across the first four weeks (fourth week measurements confirmed sustained reduction). There were no unexpected safety signals in preclinical toxicology, and petrelintide demonstrated good tolerability across DIO rat dose ranges that informed the subsequent clinical trial dose-escalation design.

ZUPREME-1 Trial Design: A Dose-Finding Clinical Trial

The ZUPREME-1 trial was a Phase 2, randomized, double-blind, placebo-controlled, dose-finding trial designed to evaluate the efficacy and safety of once-weekly petrelintide in adults with obesity or overweight. The clinical trial enrolled 493 participants across multiple treatment arms to identify the optimal dose range for further development.

Participant Population and Screening

Eligible participants were adults aged 18–75 with a body mass index (BMI) of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) with at least one weight-related co-morbidity such as cardiovascular disease, type 2 diabetes, or hypertension. Both male participants and female participants were enrolled. All participants followed a reduced-calorie diet combined with increased physical activity as background lifestyle intervention throughout the trial period.

The screening period lasted approximately 2–4 weeks before randomization. During screening, investigators assessed body weight, body mass index, fasting glucose, fasting lipids, waist circumference, and overall medical eligibility. Participants with unstable cardiovascular disease or other serious chronic disease conditions were excluded.

Treatment Arms and Dose Escalation

ZUPREME-1 used five treatment arms compared head-to-head: four active petrelintide doses and one placebo arm. All active arms received once-weekly subcutaneous administration of petrelintide with a structured dose-escalation protocol to minimize gastrointestinal adverse events during the first weeks of treatment. The dose-escalation approach — starting at a lower dose and titrating up across the fourth week through approximately the eighth week — was designed to allow the body to adapt to the amylin analog gradually.

The primary endpoint was the percentage change in body weight from baseline to week 42. Secondary endpoints included the proportion of participants achieving at least 5% and 10% body weight reduction, changes in waist circumference, fasting glucose, fasting lipids, and safety and tolerability assessments.

Detailed Efficacy Analysis: Body Weight Reduction at Week 42

The topline results from ZUPREME-1, reported on March 5, 2026, confirmed that petrelintide demonstrated clinically meaningful weight loss across the active treatment arms. At the maximally effective dose, participants achieved an average weight loss of 10.7% of body weight at week 42 versus 1.7% with placebo — a placebo-adjusted difference of approximately 9 percentage points.

Multiple treatment arms showed a dose-dependent response. Participants in the higher-dose arms lost considerably more weight than those in the lower-dose arms, confirming a clear dose-response relationship. The average weight loss in the lower-dose arms was still clinically meaningful, with participants achieving body weight reductions that exceeded the 5% threshold widely considered significant in obesity treatment clinical trials.

The proportion of participants achieving at least 5% body weight reduction was substantially higher in all active petrelintide arms compared to placebo. At the maximally effective dose, the majority of participants achieved clinically meaningful weight loss thresholds. This dose-dependent weight reduction pattern supports petrelintide’s pharmacological mechanism and provides confidence for dose selection in Phase 3 development.

Weight Loss Trajectory Over the Trial Period

Body weight reduction with once-weekly petrelintide followed a progressive trajectory over the 42-week trial period. Weight loss was observable by the fourth week and continued steadily through the second half of the treatment period. Unlike some obesity treatments that plateau early, petrelintide demonstrated ongoing weight reduction through the full trial period, suggesting that the amylin analog’s effects on body weight may not have fully plateaued at 42 weeks.

This progressive weight loss trajectory in the second half of the trial is noteworthy. Many GLP-1 receptor agonist trials show the steepest body weight changes in the first 20–30 weeks, with the curve flattening thereafter. Petrelintide’s continued weight reduction through week 42 suggests a potentially different long-term weight management profile, though longer trials are needed to confirm this observation.

Safety Profile: Adverse Events and Tolerability Data

The safety data from ZUPREME-1 are arguably as significant as the efficacy results. In the overall trial population, petrelintide demonstrated a favorable safety profile with no unexpected safety signals. Adverse events were generally mild and consistent with the known pharmacology of amylin analogs.

At the maximally effective dose, Roche reported that no participants experienced vomiting — a striking finding given that gastrointestinal adverse events are the most common reason for treatment discontinuation with current GLP-1 receptor agonist obesity treatments. No participants at the maximally effective dose discontinued treatment due to gastrointestinal adverse events.

Gastrointestinal Adverse Events Across Treatment Arms

Gastrointestinal adverse events — including nausea, vomiting, diarrhea, and constipation — are the dominant tolerability concern in the obesity drug class. In the ZUPREME-1 trial, gastrointestinal adverse events were reported at rates significantly lower than typically seen with GLP-1 receptor agonists. The placebo-like tolerability at the maximally effective dose was the most notable safety finding.

Specifically, participants who experienced vomiting in the overall trial population were concentrated in the dose-escalation phase rather than at steady state. Once participants reached their target dose, the gastrointestinal adverse events profile stabilized to near-placebo levels. This placebo-like tolerability profile during steady-state treatment is a meaningful differentiator for petrelintide in clinical practice.

Across all five treatment arms compared in ZUPREME-1, no serious unexpected safety signals emerged. Adverse events that did occur were predominantly mild to moderate in severity, and the overall discontinuation rate due to adverse events was low across all dose groups.

Body Composition and Metabolic Effects

Beyond total body weight reduction, the clinical effects of petrelintide on body composition and metabolic parameters are of significant research interest. In the ZUPREME-1 trial, secondary endpoints assessed changes in waist circumference, fasting glucose, fasting lipids, and body composition parameters including fat mass and lean mass.

Participants treated with once-weekly petrelintide showed meaningful reductions in waist circumference, consistent with preferential loss of visceral and abdominal fat mass. Changes in fasting glucose and fasting lipids were also observed, although the trial was not specifically powered for metabolic secondary endpoints.

The preservation of lean mass relative to fat mass during weight reduction is a key research question in obesity treatment. Petrelintide’s amylin-based mechanism may offer a different body composition profile compared to GLP-1 receptor agonists, though head-to-head data are not yet available. Preclinical DIO rat data suggested preferential fat mass loss, and the ZUPREME-1 clinical trial results appear directionally consistent with this observation.

Chemical and Physical Stability of Petrelintide

One of the foundational challenges in developing any amylin analog is chemical and physical stability. Native human amylin is prone to aggregation and amyloid fibril formation, which limited the practicality of earlier amylin-based therapies. Zealand Pharma’s molecular engineering addressed this through structural modifications that enhance the chemical and physical stability of the petrelintide molecule.

The resulting compound maintains physical stability at neutral pH, enabling formulation as a ready-to-use injection solution rather than requiring reconstitution. This chemical and physical stability profile is what allows once-weekly subcutaneous administration — a dosing convenience that is essential for long-term weight management adherence. Without the improved physical stability, the molecule would degrade too rapidly for a weekly dosing schedule.

Zealand Pharma has published data demonstrating that petrelintide maintains structural integrity under standard storage conditions at neutral pH for extended periods. This physical stability is a non-trivial accomplishment in the amylin analog class and represents a meaningful pharmaceutical advancement.

Roche and Zealand Pharma: Licensing and Co-Commercialization

Petrelintide originated from Zealand Pharma’s peptide engineering platform. In 2022, Roche and Zealand Pharma entered an exclusive collaboration and licensing agreement granting Roche worldwide rights to develop and co-commercialize petrelintide. Under the licensing agreement, Zealand Pharma received upfront and milestone payments, with ongoing royalties on future sales.

Zealand Pharma retains co-commercialization rights in select markets and is responsible for manufacturing the drug substance. The exclusive collaboration between Roche and Zealand Pharma extends beyond petrelintide monotherapy to include combination approaches, notably the co-formulation and co-administration programs with CT-388, a GLP-1/glucagon receptor agonist also from Zealand Pharma.

Roche’s decision to co-commercialize petrelintide signals strategic commitment to the amylin analog class. For Zealand Pharma, the partnership provides the clinical development scale and commercial infrastructure needed to advance petrelintide through Phase 3 and into global markets. Zealand Pharma continues to develop additional peptide candidates alongside the co-development of petrelintide.

Combination Potential: Co-Administration with GLP-1 Receptor Agonists

One of the most significant aspects of petrelintide’s development is its potential for co-administration with GLP-1 receptor agonist compounds. Because the long-acting amylin analog operates through a distinct pathway from GLP-1 receptor agonists, combining both mechanisms could produce additive or synergistic body weight reduction while maintaining favorable tolerability.

Roche and Zealand Pharma are planning a Phase 2 trial evaluating the co-administration of petrelintide with CT-388, a dual GLP-1/glucagon receptor agonist. The co-formulation of petrelintide and CT-388 is also being explored. If successful, this co-administration approach could position petrelintide as a foundational backbone in next-generation obesity treatment regimens.

The rationale for co-formulation of an amylin analog with a GLP-1 receptor agonist mirrors the CagriSema concept (cagrilintide + semaglutide), but with a different amylin analog and a different incretin partner. This parallel development of amylin-based co-administration strategies by multiple companies underscores the scientific consensus that amylin-pathway activation adds meaningful value to incretin-based weight management approaches.

Petrelintide in Clinical Practice: Obesity as a Chronic Disease

Obesity is now recognized as a chronic disease by major medical organizations worldwide. Effective obesity treatment requires long-term weight management strategies that patients can sustain, and the tolerability of any treatment is directly linked to adherence. In clinical practice, a significant proportion of patients discontinue GLP-1 receptor agonist therapy due to gastrointestinal adverse events, undermining the clinical effects of the treatment.

Petrelintide’s placebo-like tolerability profile, if confirmed in larger Phase 3 trials, could address this clinical practice gap. A once-weekly obesity treatment with minimal gastrointestinal adverse events would improve long-term adherence and sustain body weight reduction over years rather than months. For patients with co-morbidities such as cardiovascular disease, type 2 diabetes, or sleep apnea, sustained weight reduction is associated with meaningful improvements in disease outcomes.

The chronic disease model for obesity treatment emphasizes that weight management is a lifelong commitment. The clinical effects of any obesity treatment must be weighed against its tolerability and sustainability. Petrelintide demonstrated that meaningful body weight reduction can be achieved with placebo-like tolerability, and if this finding holds in Phase 3 clinical trials, it could reshape clinical practice guidelines for obesity treatment. Our obesity and GLP-1 landscape in the UAE article explores how these treatments are accessed regionally.

What Comes Next for Petrelintide?

Based on Roche’s March 2026 update and Zealand’s pipeline materials, two catalysts define the near-term path:

ZUPREME-2 top-line data — expected H2 2026.

Phase 2 petrelintide + CT-388 combination trial — initiation expected H1 2026.

These readouts will determine whether petrelintide’s Phase 2 profile translates into a viable late-stage development path. Track all upcoming milestones on our obesity drug approval tracker for 2026.